Original: Vaxart ( VXRT) - Get Report shares fell Monday, reversing gains in premarket trading, ahead of a presentation from the company’s founder and chief scientific officer that is expected to reveal its Phase 1 clinical trials of an oral vaccine that shows promise in protecting against COVID variants. Shares of Vaxart were up 12.62% at $12.14 in premarket trading ahead of the presentation from its founder and chief scientific officer, Dr. Sean Tucker, on the importance of T-cell immunity in COVID-19 vaccines. At the open, the stock fell 7.51% to $9.97. The oral vaccine development firm’s name has popped up frequently in social media chat rooms.